| 产品名称 | Peptides EP06817_1 | HPV 16/18 E7 11-19 (HLA-A*02:01) |
|---|---|
| 目录号 | EP06817_1 |
| 别名 | HPV 16/18 E7 11-19 (HLA-A*02:01) |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP06817_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP06817_1 | HPV 16/18 E7 11-19 (HLA-A*02:01)
品名:HPV 16/18 E7 11-19 (HLA-A*02:01)
货号:EP06817_1
规格:1 mg; 5 mg
品牌:Peptides.de
产品描述
YMLDLQPET is a linear peptide epitope corresponding to residues 11 through 19 of the E7 oncoprotein from Human papillomavirus type 16 (HPV-16, UniProt: P03129) and HPV-18 (UniProt: P06788). Classified under epitope ID 75074, this sequence is associated with the Alphapapillomavirus 9 and Alphapapillomavirus 7 species groups, respectively. This HLA-A*02:01-restricted epitope has been extensively characterized for its immunological relevance, including its capacity to be recognized by both CD8⁺ T cells and B cells. It has been tested in T cell functional assays, B cell reactivity assays, and MHC class I ligand binding studies, highlighting its value in HPV-specific immune monitoring and vaccine development. The E7 protein itself plays a central role in HPV-driven oncogenesis. It interferes with host immune responses, making E7-derived epitopes such as YMLDLQPET particularly important in the context of cancer immunotherapy research. This peptide is frequently used in experimental settings involving antigen presentation, cytotoxic T lymphocyte responses, and the evaluation of HPV-targeted immunotherapeutic strategies.
| Protein | Protein E7 |
| Species | HPV 16, HPV 18 |
| Application | Flow Cytometry |
| Indication | Infectious disease, Cancer |